Keratoprotez

Günümüzde "yapay kornea" sadece konvansiyonel greft cerrahisi ile başarı şansı olmayan hastalar için son çare olarak denenmekten öte, dünyadaki karşılanamayan allogreft ihtiyacına bağlı artan kornea kaynaklı körlüklerin önüne geçmek iddiasıda taşımaktadır. Oftalmoloji literatürüne girdiği 18. yüzyıldan beri keratoprotez tasarım ve materyallerindeki gelişmeler sayesinde cerrahi uygulama teknikleri kolaylaşmakta, retansiyon süreleri ve oranları artırmakta, görmeyi azaltıcı komplikasyonlar sınırlanmakta, prognoz iyileşmekte ve dünyada kullanımları giderek artmaktadır. Keratoprotez cerrahisinin başarısıiçin mutlak şart, doğru hasta ve cerrahi teknik seçimi ile ömür boyu takiptir.

Keratoprosthesis

Today "artificial cornea" is used not only to provide a last trial for patients with poor prognosis in conventional graft surgeries, but also to claim ending corneal blindness due to unmet allograft needs. Since 18thcentury when keratoprosthesiswas introduced to ophthalmology literature, with the improvements of its design and materials, the surgical techniques aregetting easier to perform, retention times and rates are improving, prognosis is being better, and its worldwide use has beenincreasing. The absolute term of success in keratoprosthesis surgery is correct patient and surgical technique selection andlife-long follow-up.

Kaynakça

1. Yu T, Rajendran V, Griffith M, Forrester JV, Kuffová L. High-risk corneal allografts: A therapeutic challenge. World J Transplant 2016;6(1):10-27.

2. Utine CA, Gehlbach PL, Zimmer-Galler I, Akpek EK. Permanent keratoprosthesis combined with pars plana vitrectomy and silicone oil injection for visual rehabilitation of chronic hypotony and corneal opacity. Cornea 2010;29(12):1401-5.

3. Al-Mezaine H, Wagoner MD; King Khaled Eye Spe ci a - list Hospital Cornea Transplant Study Group. Repeat penetrating keratoplasty: indications, graft survival, and visual outcome. Br J Ophthalmol 2006;90(3):324-7.

4. Weisbrod DJ, Sit M, Naor J, Slomovic AR. Outcomes of repeat penetrating keratoplasty and risk factors for graft failure. Cornea 2003;22(5):429-34.

5. Beckingsale P, Mavrikakis I, Al-Yousuf N, Mavrikakis E, Daya SM. Penetrating keratoplasty: outcomes from a corneal unit compared to national data. Br J Ophthalmol 2006;90(6):728-31.

6. Aasuri MK, Garg P, Gokhle N, Gupta S. Penetrating ke ratoplasty in children. Cornea 2000;19(2):140-4.

7. Sharma N, Prakash G, Titiyal JS, Tandon R, Vajpayee RB. Pediatric keratoplasty in India: indications and outcomes. Cornea 2007;26(7):810-3.

8. Al-Ghamdi A, Al-Rajhi A, Wagoner MD. Primary pediatric keratoplasty: indications, graft survival, and visual outcome. J AAPOS 2007;11(1):41-7.

9. Dana MR, Schaumberg DA, Moyes AL, Gomes JA. Corneal transplantation in children with Peters anomaly and mesenchymal dysgenesis. Multicenter Pe diat - ric Keratoplasty Study. Ophthalmology 1997;104(10): 1580-6.

10. Aquavella JV, Gearinger MD, Akpek EK, McCormick GJ. Pediatric keratoprosthesis. Ophthalmology 2007; 114(5):989-94.

11. Tan DT, Dart JK, Holland EJ, Kinoshita S. Corneal transplantation. Lancet 2012;379(9827):1749-61.

12. Williams KA, Lowe M, Bartlett C, Kelly TL, Coster DJ; All Contributors. Risk factors for human corneal graft failure within the Australian corneal graft registry. Transplantation 2008;86(12):1720-4.

13. Bersudsky V, Blum-Hareuveni T, Rehany U, Rumelt S. The profile of repeated corneal transplantation. Ophthalmology 2001;108(3):461-9.

14. Thompson RW Jr, Price MO, Bowers PJ, Price FW Jr. Long-term graft survival after penetrating keratoplasty. Ophthalmology 2003;110(7):1396-402.

15. Yildiz E, Hoskins E, Fram N, Rapuano CJ, Ham mer - smith KM, Laibson PR, Cohen EJ. Third or greater penetrating keratoplasties: indications, survival, and visual outcomes. Cornea 2010;29(3):254-9.

16. Dohlman C. Foreword. In: Keratoprostheses and Arti - fi cial Corneas, Fundamentals and Surgical Appli - cations. Eds: Cortina MS, de la Cruz J. ©Springer-Ver - lag Berlin Heidelberg 2015.

17. Ament JD, Todani A, Pineda R 2nd, Shen TT, Aldave AJ, Dohlman CH, Chodosh J. Global corneal blindness and the Boston keratoprosthesis type I. Am J Ophthalmol 2010;149(4):537-9.

18. Eye Bank Association of America. 2013 Eye Banking Statistical Report.

19. Van Meter W, Sheth PH. Potential Adverse Effects on the Cornea Donor Pool in 2031. International Journal of Eye Banking 2013;1(2):1-9.

20. Mannis M, Dohlman C. The artificial cornea: a brief history. In: History of Ophthalmology Wayenborgh; 1999. p.321-36.

21. Lee SH, Cortina MS, de la Cruz J. History of the Artificial Cornea In: Keratoprostheses and Arti¬ficial Corneas, Fundamentals and Surgical Applications. Eds: Cortina MS, de la Cruz J.© Springer-Verlag Heidelberg 2015.

22. Dohlman CH, Schneider HA, Doane MG. Prostho - keratoplasty. Am J Ophthalmol 1974:77(5):694-70.

23. Goldman DR, Hubschman JP, Aldave AJ, Chiang A, Huang JS, Bourges JL, Schwartz SD. Postoperative posterior segment complications in eyes treated with the Boston type I keratoprosthesis. Retina 2013; 33(3):532-41.

24. Dunlap K, Chak G, Aquavella JV, Myrowitz E, Utine CA, Akpek E. Short-term visual outcomes of Boston type 1 keratoprosthesis implantation. Ophthalmology 2010;117(4):687-92.

25. Greiner MA, Li JY, Mannis MJ. Longer-term vision outcomes and complications with the Boston type 1 keratoprosthesis at the University of California, Davis. Ophthalmology 2011;118(8):1543-50.

26. Yaghouti F1, Nouri M, Abad JC, Power WJ, Doane MG, Dohlman CH. Keratoprosthesis: preoperative prognostic categories. Cornea 2001;20(1):19-23.

27. Sayegh RR, Ang LP, Foster CS, Dohlman CH. The Boston keratoprosthesis in Stevens-Johnson syndrome. Am J Ophthalmol 2008;145(3):438-44.

28. Akpek EK, Aldave AJ, Aquavella JV. The use of precut, ?-irradiated corneal lenticules in Boston type 1 keratoprosthesis implantation. Am J Ophthalmol

29. Robert M, Biernacki K, Harissi-Dagher M. Boston keratoprosthesis type 1 surgery: use of frozen versus fresh corneal donor carriers. Cornea 2012;31(4):339- 45.

30. Shihadeh WA, Mohidat HM. Outcomes of the Boston keratoprosthesis in jordan. Middle East Afr J Ophthal - mol 2012;19(1):97-100.

31. Cruzat A, Tauber A, Shukla A, Paschalis EI, Pineda R, Dohlman CH. Low-cost and readily available tissue carriers for the Boston keratoprosthesis: a review of possibilities. J Ophthalmol 2013;2013:686587.

32. Rudnisky CJ, Belin MW, Todani A, Al-Arfaj K, Ament JD, Zerbe BJ, Ciolino JB; Boston Type 1 Keratop - rosthesis Study Group. Risk factors for the development of retroprosthetic membranes with Boston keratoprosthesis type 1: multicenter study results. Ophthalmology 2012;119(5):951-5.

33. Stacy RC, Jakobiec FA, Michaud NA, Dohlman CH, Colby KA. Characterization of retrokeratoprosthetic membranes in the Boston type 1 keratoprosthesis. Arch Ophthalmol 2011;129(3):310-6.

34. Ahmad S, Akpek EK, Gehlbach PL, Dunlap K, Ra mu - lu PY. Predictors of visual outcomes following Boston type 1 keratoprosthesis implantation. Am J Ophthal - mol 2015;159(4):739-47.

35. Zerbe BL, Belin MW, Ciolino JB; Boston Type 1 Kera - toprosthesis Study Group. Results from the multicenter Boston Type 1 Keratoprosthesis Study. Ophthal - mology 2006;113(10):1779.

36. Greiner MA, Li JY, Mannis MJ. Longer-term vision outcomes and complications with the Boston type 1 keratoprosthesis at the University of California, Davis. Ophthalmology 2011;118:1543-50.

37. Netland PA, Terada H, Dohlman CH. Glaucoma associated with keratoprosthesis. Ophthalmology 1998; 105(4):751-7.

38. Talajic JC, Agoumi Y, Gagné S, Moussally K, HarissiDagher M. Prevalence, progression, and impact of glaucoma on vision after Boston type 1 keratoprosthesis surgery. Am J Ophthalmol 2012;153(2):267-74.

39. Rivier D, Paula JS, Kim E, Dohlman CH, Grosskreutz CL. Glaucoma and keratoprosthesis surgery: role of adjunctive cyclophotocoagulation. J Glaucoma 2009; 18(4):321-4.

40. Dohlman CH, Grosskreutz CL, Chen TC, Pasquale LR, Rubin PA, Kim EC, Durand M. Shunts to divert aqueous humor to distant epithelialized cavities after keratoprosthesis surgery. J Glaucoma 2010;19(2): 111-5.

41. Dokey A, Ramulu PY, Utine CA, Tzu JH, Eberhart CG, Shan S, Gelhbach PL, Akpek EK. Chronic hypotony associated with the Boston type 1 keratoprosthesis. Am J Ophthalmol 2012;154(2):266-271.

42. Utine CA, Tzu JH, Akpek EK. Clinical features and prog nosis of Boston type I keratoprosthesis-associated corneal melt. Ocul Immunol Inflamm 2011;19 (6):413-8.

43. Robert MC, Crnej A, Shen LQ, Papaliodis GN, Dana R, Foster CS, Chodosh J, Dohlman CH. Infliximab after Boston keratoprosthesis in Stevens-Johnson Syndrome: An update. Ocul Immunol Inflamm 2016; 25:1-5.

44. Robert MC, Arafat SN, Ciolino JB. Collagen crosslinking of the Boston keratoprosthesis donor carrier to prevent corneal melting in high-risk patients. Eye Contact Lens 2014;40(6):376-81.

45. Tay E, Utine CA, Akpek EK. Crescenteric amniotic membrane grafting in keratoprosthesis-associated corneal melt. Arch Ophthalmol 2010;128(6):779-82.

46. Eghrari AO, Ahmad S, Ramulu P, Iliff NT, Akpek EK. The usage of a conjunctival flap to improve retention of Boston type 1 keratoprosthesis in severe ocular surface disease. Ocul Immunol Inflamm 2016;24 (5): 555-60.

47. 10th KPro Study Group Meeting, Program & Abst racts. April 22-23, 2016, Kyoto, Japan.

48. Coassin M, Zhang C, Green WR, Aquavella JV, Akpek EK. Histopathologic and immunologic aspects of alphacor artificial corneal failure. Am J Ophthalmol 2007;144:694-700.

49. Ngakeng V, Hauck MJ, Price MO, Price FW. AlphaCor keratoprosthesis: a novel approach to minimize the risks of long-term postoperative complications. Cor - nea 2008;27:905-10.

50. Pineda II R, Shiuey Y. The KeraKlear artificial cornea: a novel keratoprosthesis. Tech Ophthalmology 2009; 7(3):101-4.

Kaynak Göster